Back to Search
Start Over
Phase 1 study assessing dovitinib (TKI258) on the pharmacokinetics of caffeine, diclofenac, omeprazole, and midazolam in patients with advanced solid tumors
- Source :
- Journal of Clinical Oncology. 32:2581-2581
- Publication Year :
- 2014
- Publisher :
- American Society of Clinical Oncology (ASCO), 2014.
-
Abstract
- 2581 Background: Dovitinib (TKI258) is an oral tyrosine kinase inhibitor targeting kinases involved in tumor cell proliferation and survival, including FGFR, VEGFR, PDGFR, c-KIT, and FLT3. In vitro...
- Subjects :
- Cancer Research
biology
medicine.drug_class
business.industry
Kinase
Pharmacology
Tyrosine-kinase inhibitor
In vitro
chemistry.chemical_compound
Diclofenac
Oncology
Pharmacokinetics
chemistry
embryonic structures
cardiovascular system
medicine
biology.protein
biological phenomena, cell phenomena, and immunity
business
Caffeine
Omeprazole
Platelet-derived growth factor receptor
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 32
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........18b563a631a592b1c9067f5d0ce79e21